Tissue kallikrein-1 for treating chronic kidney disease
AssigneeDiaMedica Inc.
InventorsRick PAULS, David Wambeke, Nick Paulson
Life of this patent
Estimating the term…
Abstract
Provided are methods of using human tissue kallikrein-1 (KLK1) to treat chronic kidney disease (CKD) in patients having salt-sensitive hypertension and low KLK1 levels, including methods of identifying and treating optimal sub-populations of CKD patients based on selected genotypes and/or phenotypes.
Claims31
A method of treating chronic kidney disease (CKD) in a patient in need thereof, comprising administering to the patient a pharmaceutical composition that comprises one or more tissue kallikrein (KLK1) polypeptides, wherein the patient has low KLK1 levels and/or salt-sensitive hypertension.
(canceled)
20-23. (canceled)
34-39. (canceled)
Dependencies are inferred from the claim text.